#1 Clinical Trials Search in Europe

Study on the Effectiveness of Amoxicillin and Clavulanic Acid in Treating Chronic Wet Cough in Young Children

3 1 1

What is this study about?

The study focuses on young children who have a persistent cough that produces mucus, known as a chronic wet cough. The treatment being tested is a medication called Augmentin, which is a combination of two substances: amoxicillin and clavulanic acid. These substances work together to fight bacterial infections. The study will compare the effects of this medication to a placebo, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to see if children with a chronic wet cough improve more when they take Augmentin for 14 days compared to those who take a placebo. Additionally, the study will explore whether extending the treatment to 28 days affects the time it takes for the cough to return. The study will also look at how the bacteria in the airways and gut, as well as inflammation and genetics, might influence the cough and its treatment.

Participants in the study will receive either the medication or the placebo for a set period. Researchers will monitor the children’s symptoms and any changes in their cough. The study will also examine the presence of bacteria and viruses, the diversity of bacteria in the airways and gut, and markers of inflammation in the body. The goal is to understand how these factors relate to the cough and its treatment, and to assess the overall quality of life for the children involved.

1 joining the study

Upon joining the study, the participant will be assessed to ensure they meet the necessary criteria. This includes being between the ages of 9 and 36 months, weighing between 7 kg and 24 kg, and having a chronic wet cough for more than 4 weeks. Written consent from both parents is required.

2 initial assessment

The participant’s cough will be evaluated using a **verbal category descriptive (VCD) cough score**. This score ranges from 0 to 10, with parents reporting the average score over the three days before treatment begins.

3 treatment phase

Participants will receive either **amoxicillin-clavulanate** or a placebo. The medication is administered as an **oral suspension** with a mixed fruit flavor. The dosage is 400 mg/57 mg per 5 ml.

The treatment will last for either 14 or 28 days, depending on the group assignment. The purpose is to determine if the response to treatment is higher in those receiving the antibiotic compared to the placebo.

4 monitoring and reporting

Throughout the treatment, parents will report the participant’s cough score daily. A response to treatment is defined as a reduction in the cough score to 2 or less, or the cessation of coughing for at least 3 days during the treatment period.

5 follow-up

After the treatment phase, the participant will be monitored for any relapse of symptoms. A relapse is defined as a new period of wet cough lasting more than four weeks or an episode of at least two weeks that requires antibiotic treatment.

6 final assessment

The study will conclude with a final assessment of the participant’s health and any changes in their condition. This includes evaluating the diversity and composition of the airway and gut microbiome, as well as any inflammatory markers.

Who Can Join the Study?

  • Child’s age must be more than 9 months and less than 36 months.
  • Child’s body weight must be more than 7 kg and less than 24 kg.
  • Child must have been born at full term, which means after 37 weeks of pregnancy.
  • Child must have a chronic wet cough for more than 4 weeks at the time of screening. This means a cough that produces mucus and has been ongoing for a long time.
  • The average cough score over the last 7 days must be 4 points or more, and there should be no signs of another cause for the cough.
  • Registration for the study must be at least 5 days before starting.
  • Both parents must provide written informed consent, which means they agree to let their child participate in the study after understanding all the details.
  • The child must be eligible for treatment with Augmentin, which is a type of antibiotic medication.

Who Cannot Join the Study?

  • Children who do not have a chronic wet cough. A chronic wet cough is a cough that produces mucus and lasts for a long time.
  • Children who are not within the age range specified for the study.
  • Children who have other medical conditions that might interfere with the study.
  • Children who are currently taking medications that could affect the study results.
  • Children who have allergies to the study medication, which is amoxicillin-clavulanate. This is a type of antibiotic used to treat infections.
  • Children who have participated in another clinical trial recently.
  • Children who have a history of severe reactions to antibiotics.
  • Children who are unable to follow the study procedures for any reason.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oslo Universitetssykehus HF Oslo Norway

Other Sites

Site Name City Country Status
Universitetssykehuset Nord-Norge HF Tromsø Norway
St. Olavs Hospital HF Trondheim Norway
Hfvpr Buxcfk Hl Bergen Norway
Hpgwk Sstzpvoic Hc Stavanger Norway
Afjcmoro Uobkacpbwy Hzneoisk Lorenskog Norway
Hjizp Mggnu Oj Rkdrqly Hh Aalesund Norway

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Norway Norway
Recruiting
01.05.2023

Trial locations

Investigated drugs:

Amoxicillin-Clavulanate is a combination antibiotic used in this study to treat children with chronic wet cough. It works by killing bacteria that may be causing the cough. Amoxicillin is a type of penicillin that fights bacteria, while clavulanate helps prevent certain bacteria from becoming resistant to amoxicillin. In this trial, researchers are investigating whether taking this medication for 14 days helps improve symptoms more effectively than not taking it. They are also studying if extending the treatment to 28 days affects how quickly symptoms return after stopping the medication.

Investigated diseases:

Chronic Wet Cough – Chronic wet cough is a persistent cough that produces phlegm or mucus and lasts for an extended period, typically more than four weeks. It is often seen in young children and can be a sign of underlying respiratory issues. The cough is characterized by a wet or productive sound, indicating the presence of mucus in the airways. Over time, the cough may fluctuate in intensity and frequency, sometimes improving temporarily before worsening again. The condition can be associated with repeated respiratory infections or inflammation in the airways. It may also be linked to environmental factors or underlying health conditions affecting the respiratory system.

Trial ID:
2022-500586-27-00
Protocol code:
AMIC 002
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Effectiveness of Fluticasone Propionate and Amoxicillin-Clavulanic Acid for Children with Long-Lasting Cough

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effectiveness and Safety of Camlipixant for Adults with Refractory or Unexplained Chronic Cough

    Not yet recruiting

    3 1
    Investigated drugs:
    Czechia Germany Poland Slovakia